Professor A Xu
Department of Pharmacology & Pharmacy, The University of Hong Kong
Professor Aimin Xu (徐愛民)
BMed Anhui, MSc, PhD Auck
Director, State Key Laboratory of Pharmaceutical Biotechnology, HKU (www.sklpb.hku.hk)
Director, Antibody and Immunoassay Services, HKU
Deputy Chair, Biochemical Journal
American Diabetes Association
American society of Biochemistry and Molecular Biology HBHA center, HKU
Editor: Clinical Science, PLOS One
Editorial Board member, Journal of Obesity, Journal of Diabetes, Adipocytes, Cardiovascular Drugs and Therapy Editor
Obesity is a major risk factor of type 2 diabetes (T2DM), insulin resistance and cardiovascular diseases (CVDs). In obesity, chronic metabolic stresses trigger adipose tissue inflammation and promote macrophage infiltration, resulting in aberrant secretion of bioactive peptides (known as adipokines). Our primary research interest is to investigate the role of adipokines in the pathogenesis of obesity-related insulin resistance, systemic inflammation, T2DM and vascular dysfunctions in animal models and human subjects. Our long-term goal is to develop adipokine-based diagnostic and therapeutic strategies for obesity-related cardio-metabolic complications.
Professor Xu and his research associates (click image to enlarge)
Lin Z, Tian H, Lam KS, Lin S, Hoo RC, Konishi M, Itoh N, Wang Y, Bornstein SR, Xu A*, Li X. Adiponectin mediates the metabolic effects of FGF21 on glucose homeostasis and insulin sensitivity in mice. Cell Metabolism. 2013, 17:779-89 (cited ~30 times within 8 months after publication)
Cheng KK, Lam KS, Wu D, Wang Y.. and Xu A*. APPL1 potentiates insulin secretion in pancreatic beta-cells by increasing Akt-dependent expression of SNARE proteins in mice. Proc. Natl. Acad. Sci. USA. 2012, 109:8919-24, selected for commentary.
Li FY, Lam KS, Tse HF, Chen C, Wang Y, Vanhoutte PM, Xu A*. Endothelium-selective activation of AMP-activated protein kinase prevents diabetes mellitus-induced impairment in vascular function and reendothelialization via induction of heme oxygenase-1 in mice. Circulation. 2012, 126:1267-77.
Ye D, Li Y, Lam KS, Li H, Jia W, Wang Y, Man K, Li X and Xu A*. TLR4 mediates obesity-induced nonalcoholic steatohepatitis through activation of X-box binding protein in mice. Gut. 2012, 61: 1058-67
Wang Y, Cheng KK, Lam KS, Wu D, Wang Y, Huang Y, Vanhoutte PM, Sweeney G, Li Y, Xu A*. APPL1 counteracts obesity-induced vascular insulin resistance and endothelial dysfunction by modulating the endothelial production of nitric oxide and endothelin-1 in mice. Diabetes, 2011, 60: 3044-54.
Wong WT, Tian XY, Xu A*, Yu J, Lau CW, Hoo R, Wang Y, Lee VW, Lam KS, Vanhoutte PM, and Huang Y. The obligatory role of adiponectin in restoring endothelial function in PPARγ agonist-treated diabetic mice. Cell Metabolism, 2011, 16:101-15.
Chang J , Li Y , Huang Y , Lam KS, Hoo LC, Wong WT, Cheng KK, Wang Y, Vanhoutte PM , and Xu A*. Adiponectin Prevents Diabetic Premature Senescence of Endothelial Progenitor Cells and Promotes Endothelial Repair by Suppressing the p38 MAP kinase/p16INK4A Signaling Pathway. Diabetes, 2010, 59: 2949-59
Cheng KK, Iglesias MA, Lam KS, Wang Y, Sweeney, Zhu W, Vanhoutte PM, Kraegen EW and Xu A*. APPL1 Potentiates Insulin-mediated Inhibition of Hepatic Glucose Production and Alleviates Diabetes via Akt Activation in Mice. Cell Metabolism, 2009, 9:417-27.
Zhang X, Yeung DC, Karpisek M, Stejskal D, Zhou ZG, Liu F, Wong RL, Chow WS, Tso AW, Lam KS, Xu A*. Serum FGF21 levels are increased in obesity and are independently associated with the metabolic syndrome in humans. Diabetes, 2008, 57:1246-53.
Cheng KK, Lam KS, Wang Y, Huang Y, Carling D, Wu D, Wong C, Xu A*. Adiponectin-induced endothelial nitric oxide synthase activation and nitric oxide production are mediated by APPL1 in endothelial cells. Diabetes. 2007, 56:1387-94 (cited over 170 times).
Xu A*, Lam MCL, Chan KW, Wang Y, Hoo RCL, Zhang JL, Tso A and Lam KSL, ANGPTL4 decreases blood glucose, improve glucose tolerance, but induces hyperlipidemia and hepatic steatosis in mice, Proc. Natl. Acad. Sci. USA, 2005, 102, 6089-6091
Xu A*, Wang Y, Keshaw H, Xu LY, Lam KS, Cooper GJ. The fat-derived hormone adiponectin alleviates alcoholic and nonalcoholic fatty liver diseases in mice. J. Clin. Invest. 2003, 112:91-100. (selected for the cover story of this issue, CITED OVER 980 times).
Professor A Xu
8/F, 21 Sassoon Road, Li Ka Shing Faculty of Medicine, Laboratory Block, Faculty of Medicine Building, Hong Kong SAR, China.
Dr. Gary Sweeney, York University, Canada.
Prof. Edward Kraegen, Garvin's institute, Australia.
Prof. Jia Weiping, Shanghai Diabetes Center, China
Theme-based Research Scheme (T12-705/11) - Co-I
- Personalized medicine for cardiovascular diseases
General Research Fund (784111M) -PI
- The Liver-derived Hormone FGF21 as a Novel Regulator of Vascular Function: Molecular Basis and Physiological Implications
RGC collaborative research fund (HKU4/CRF/10) -PI
- A multiple disciplinary approach to investigate vascular dysfunction in obesity and diabetes: From molecular mechanism to therapeutic intervention
National "973" basic research on diabetes matching fund (2011CB504004) -PI
- 2型糖尿病发生发展的分子机制研究 (Molecular basis of type 2 diabetes).
General Research Fund (783010M) -PI
- APPL2 as a Negative Regulator of Insulin Sensitivity and Glucose Uptake in Skeletal Muscle: A Novel Pathway Leading to Insulin Resistance?
RGC collaborative Research Fund (HKU 3/CRF/09) - Co-I
- To Establish a Metabolic Study Center in Hong Kong: Focusing on the liver-derived hormones
General Research fund (781309M) -PI
- Characterization of Novel Adaptor Proteins Involved in Regulating Insulin Sensitivity and Glucose Homeostasis: from Molecular Mechanism to Physiological Implication
NSFC/RGC joint research scheme 2008 (NHKU 735_08) -PI
- Adipocyte fatty acid binding protein as a novel diagnostic marker and therapeutic target to combat vascular complications of diabetes: mechanisms and clinical implications
General Research Fund 2008 (779608M) -PI
- Protective roles of AMP-activated protein kinase against vascular disease in diabetes: Molecular mechanisms and therapeutic intervention
Antibody and Immunoassay Services